Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S2.54
P/E—
Fwd P/E18.10
PEG0.93
52W— – —
RSI—
Target$276.28 (+5.5%)
Beta1.19
Div—
Loading chart…
RSI ()
Loading patterns…
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 60
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
8Bullish
5Bearish
0Neutral
Key Signals 2
▲ Double Bottom
Major reversal
2026-06-26 · $190.68
Two lows ~$161.99 — bullish reversal confirmed
Learn more →
▲ Double Bottom
Major reversal
2026-08-19 · $245.3
Two lows ~$230.45 — bullish reversal confirmed
Learn more →
Momentum Signals 11
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ Bull Flag
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
STRONG BUY
BuyHoldSell
Price Target Range
$276.28
+5.5% upside
Low $240
—
High $300
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
32.97%Last 12 Months
Operating Margin
13.03%Last 12 Months
Return on Equity
22.82%Last 12 Months
Revenue Growth
8.70%Year over Year
Free Cash Flow
2.15BLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
257.98Most Recent Quarter
Current Ratio
0.71Most Recent Quarter
Cash
2.08BMost Recent Quarter
Total Debt
16.25BMost Recent Quarter
Net Debt
—Most Recent Quarter
How IQV Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 43.09B |
| Enterprise Value | 57.39B |
| Trailing P/E | 32.60 |
| Forward P/E | 18.10 |
| PEG Ratio (5yr) | 0.93 |
| Price/Sales (ttm) | 2.54 |
| Price/Book (mrq) | 6.98 |
| EV/Revenue | 3.38 |
| EV/EBITDA | 18.83 |
Share Statistics
| Avg Vol (3m) | 1.44M |
| Shares Outstanding | 164.60M |
| Float | 156.25M |
| % Held by Insiders | 1.09% |
| % Held by Institutions | 103.42% |
| Short Ratio | 3.00 |
| Short % of Float | 2.66% |
Profitability
| Gross Margin | 32.97% |
| Operating Margin (ttm) | 13.03% |
| Profit Margin | 8.10% |
| Return on Assets (ttm) | 5.06% |
| Return on Equity (ttm) | 22.82% |
Income Statement
| Revenue (ttm) | 16.98B |
| Revenue Growth (yoy) | 8.70% |
| Gross Profit (ttm) | 5.60B |
| EBITDA | 3.05B |
| Net Income (ttm) | 1.38B |
| Diluted EPS (ttm) | 8.03 |
| EPS Growth (yoy) | -0.60% |
Balance Sheet
| Total Cash (mrq) | 2.08B |
| Total Debt (mrq) | 16.25B |
| Debt / Equity (mrq) | 257.98 |
| Current Ratio (mrq) | 0.71 |
| Book Value / Share | 37.49 |
| Operating CF (ttm) | 2.82B |
| Free Cash Flow (ttm) | 2.15B |
Trading & Dividends
| Beta (5Y) | 1.19 |
| 50-Day MA | 234.05 |
| 200-Day MA | 202.50 |
| Fwd Dividend Yield | N/A |
| Payout Ratio | 0.00% |
No dividend history available for IQV.
Ownership Breakdown
Institutional 103.42%
Insider 1.09%
Short Interest
2.66% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in IQV in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|